{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:40:59Z","timestamp":1792726859522,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.berh.2026.102206","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:29:33Z","timestamp":1792726173000},"page":"102206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of biomarkers in the management of osteoporosis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6785-9744","authenticated-orcid":false,"given":"Irakli","family":"Tskhakaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Saag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.berh.2026.102206_bib3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.beem.2018.05.003","article-title":"Bone turnover: biology and assessment tools","volume":"32","author":"Szulc","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.berh.2026.102206_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116148","article-title":"Aspects of intercellular communication in bone and implications in therapy","volume":"153","author":"John Martin","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.berh.2026.102206_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fbioe.2018.00134","article-title":"In vitro models of bone remodelling and associated disorders","volume":"6","author":"Owen","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00223-021-00930-4","article-title":"Practical considerations for the clinical application of bone turnover markers in osteoporosis","volume":"112","author":"Vasikaran","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"10.1016\/j.berh.2026.102206_bib8","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.berh.2026.102206_bib9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00223-021-00816-5","article-title":"A multicenter study to evaluate harmonization of assays for C-Terminal telopeptides of type I collagen (\u00df-CTX): a report from the IFCC-IOF committee for bone metabolism (C-BM)","volume":"108","author":"Cavalier","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"9321","key":"10.1016\/j.berh.2026.102206_bib10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.berh.2026.102206_bib11","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.2106\/JBJS.20.01071","article-title":"Fracture risk assessment: an update","volume":"103","author":"Cozadd","year":"2021","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","author":"Johansson","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"18","key":"10.1016\/j.berh.2026.102206_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.berh.2026.102206_bib15","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","article-title":"Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib16","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","article-title":"National bone health alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges","volume":"23","author":"Bauer","year":"2012","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.berh.2026.102206_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","article-title":"Effect of feeding on bone turnover markers and its impact on biological variability of measurements","volume":"30","author":"Clowes","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.berh.2026.102206_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1702413","article-title":"Novel aspects of biochemical assessment of bone remodeling and mineralization","volume":"16","author":"Leszczy\u0144ska","year":"2025","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00223-022-01020-9","article-title":"New emerging biomarkers for bone disease: Sclerostin and Dickkopf-1 (DKK1)","volume":"112","author":"Dincel","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-022-06523-7","article-title":"Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders","volume":"34","author":"Marini","year":"2023","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"10.1016\/j.berh.2026.102206_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/jcm11030806","article-title":"The role of sclerostin in bone diseases","volume":"11","author":"Vasiliadis","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","article-title":"Sclerostin: from bench to bedside","volume":"39","author":"Tanaka","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib24","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/jbmr.3803","article-title":"Mendelian randomization analysis reveals a causal influence of circulating sclerostin levels on bone mineral density and fractures","volume":"34","author":"Zheng","year":"2019","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jbmr.2342","article-title":"Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women","volume":"30","author":"Reppe","year":"2015","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"18","key":"10.1016\/j.berh.2026.102206_bib26","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.3390\/ijms21186927","article-title":"Circulating MicroRNAs as novel biomarkers for osteoporosis and fragility fracture risk: is there a use in assessment risk?","volume":"21","author":"Ciuffi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s40200-021-00873-5","article-title":"A systematic review of miRNAs as biomarkers in osteoporosis disease","volume":"20","author":"Hasanzad","year":"2021","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib28","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1038\/s41598-018-26525-y","article-title":"Circulating microRNAs as potential diagnostic biomarkers for osteoporosis","volume":"8","author":"Mandourah","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2026.102206_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108331","article-title":"Evaluation of circulating miRNA-208a-3p, miRNA-155-5p and miRNA-637 as potential non-invasive biomarkers and the possible mechanistic insights into pre- and postmenopausal osteoporotic females","volume":"684","author":"Ismail","year":"2020","journal-title":"Arch Biochem Biophys"},{"issue":"11","key":"10.1016\/j.berh.2026.102206_bib30","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1210\/jc.2016-2365","article-title":"Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures","volume":"101","author":"Kocijan","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287458","article-title":"Up-regulation of plasma miRNA-21 and miRNA-422a in postmenopausal osteoporosis","volume":"18","author":"Mohammadisima","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/clinem\/dgac667","article-title":"Circulating miRNAs respond to denosumab treatment after 2 years in postmenopausal women with osteoporosis-the MiDeTe study","volume":"108","author":"Messner","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12916-025-04601-1","article-title":"Polygenic risk score-guided personalized osteoporosis screening: a population-based study","volume":"24","author":"Wang","year":"2026","journal-title":"BMC Med"},{"issue":"14","key":"10.1016\/j.berh.2026.102206_bib34","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.3390\/ijms25147526","article-title":"Proteomic biomarkers associated with low bone mineral density: a systematic review","volume":"25","author":"Becerra-Cervera","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.berh.2026.102206_bib35","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3109\/s10165-011-0455-2","article-title":"Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort","volume":"21","author":"Yoshimura","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S8756-3282(00)00325-2","article-title":"Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study","volume":"27","author":"Chapurlat","year":"2000","journal-title":"Bone"},{"issue":"10102","key":"10.1016\/j.berh.2026.102206_bib37","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00774-019-01057-1","article-title":"Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial","volume":"38","author":"Takada","year":"2020","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2004","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.berh.2026.102206_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jare.2024.10.019","article-title":"Plasma proteomic profiles reveal proteins and three characteristic patterns associated with osteoporosis: a prospective cohort study","volume":"75","author":"Zheng","year":"2025","journal-title":"J Adv Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00774-020-01175-1","article-title":"Discovery of the RANKL\/RANK\/OPG system","volume":"39","author":"Yasuda","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1210\/jcem-64-4-681","article-title":"Serum osteocalcin and total body calcium in normal pre- and postmenopausal women and postmenopausal osteoporotic patients","volume":"64","author":"Yasumura","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"9\u201310","key":"10.1016\/j.berh.2026.102206_bib44","first-page":"499","article-title":"Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin Lab"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40520-014-0296-x","article-title":"Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover","volume":"27","author":"Mukaiyama","year":"2015","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2362.1996.142304.x","article-title":"Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases","volume":"26","author":"Gonnelli","year":"1996","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib47","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-023-03668-1","article-title":"Association of serum osteocalcin with bone microarchitecture and muscle mass in Beijing community-dwelling postmenopausal women","volume":"84","author":"Liu","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN110705","article-title":"Serum osteocalcin concentration as an independent biomarker of osteoporosis in patients with chronic kidney disease","volume":"98","author":"Chi","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.berh.2026.102206_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116353","article-title":"RANKL biology","volume":"159","author":"Takegahara","year":"2022","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/jcp.2010.086595","article-title":"Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis","volume":"64","author":"Jabbar","year":"2011","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.berh.2026.102206_bib52","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1210\/clinem\/dgac293","article-title":"Circulating MicroRNAs as biomarkers of osteoporosis and fragility fractures","volume":"107","author":"Ciuffi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib53","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz300","article-title":"Circulating miR-181c-5p and miR-497-5p are potential biomarkers for prognosis and diagnosis of osteoporosis","volume":"105","author":"Ma","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2026.102206_bib54","first-page":"37","article-title":"An updated overview of the search for biomarkers of osteoporosis based on human proteomics","volume":"49","author":"Wang","year":"2024","journal-title":"J Orthop Transl"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib55","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/cells15050472","article-title":"Profiling osteoporosis via integrated multi-omics technologies","volume":"15","author":"Braile","year":"2026","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.berh.2026.102206_bib56","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/jor.25628","article-title":"Discovery of novel serum biomarkers for diagnosing and predicting postmenopausal osteoporosis patients by 4D-label free protein omics","volume":"41","author":"Li","year":"2023","journal-title":"J Orthop Res Off Publ Orthop Res Soc"},{"issue":"06.25329139","key":"10.1016\/j.berh.2026.102206_bib57","first-page":"6","article-title":"Bayesian genome-wide polygenic score integration with FRAX for enhanced fracture risk prediction in postmenopausal women","volume":"2025","author":"Liu","year":"2025","journal-title":"MedRxiv Prepr Serv Health Sci"},{"key":"10.1016\/j.berh.2026.102206_bib58","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-026-01497-8","article-title":"Advanced bayesian BMD-derived genome-wide polygenic scores enhance clinical FRAX-based fracture risk prediction in postmenopausal women","volume":"117","author":"Liu","year":"2026","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-021-00838-6","article-title":"Improved prediction of fracture risk leveraging a genome-wide polygenic risk score","volume":"13","author":"Lu","year":"2021","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib60","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jama.2025.6003","article-title":"Osteoporosis: a review","volume":"334","author":"Morin","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.berh.2026.102206_bib61","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00223-022-00996-8","article-title":"Bone turnover marker profiling and fracture risk in older women: fracture risk from Age 75 to 90","volume":"111","author":"Ivaska","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib63","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1359\/jbmr.091006","article-title":"Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years","volume":"25","author":"Ivaska","year":"2010","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.berh.2026.102206_bib64","article-title":"Bone turnover markers (\u03b2-CTX, PINP, ALP) in osteoporosis: correlation with bone loss and fracture risk stratification","volume":"16","author":"Wu","year":"2025","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12891-025-08571-6","article-title":"Association between bone turnover markers and FRAX predicted fracture risk in Chinese adults: a cross-sectional study","volume":"26","author":"Qu","year":"2025","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.berh.2026.102206_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6794837","article-title":"The effect of clothing on vitamin D status, bone turnover markers, and bone mineral density in young Kuwaiti females","volume":"2019","author":"Al-Yatama","year":"2019","journal-title":"Int J Endocrinol"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"10.1016\/j.berh.2026.102206_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.09.002","article-title":"Current use of bone turnover markers in the management of osteoporosis","volume":"109\u2013110","author":"Brown","year":"2022","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib69","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"8","key":"10.1016\/j.berh.2026.102206_bib70","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib71","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.berh.2026.102206_bib72","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib73","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.berh.2026.102206_bib74","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.berh.2026.102206_bib76","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","article-title":"PINP as a biological response marker during teriparatide treatment for osteoporosis","volume":"25","author":"Krege","year":"2014","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"7","key":"10.1016\/j.berh.2026.102206_bib77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.berh.2026.102206_bib78","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for Postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.berh.2026.102206_bib79","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2026.102206_bib80","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib82","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment\u2010related changes in bone turnover and fracture risk reduction in clinical trials of anti\u2010resorptive drugs: a meta\u2010regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.berh.2026.102206_bib83","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.berh.2026.102206_bib84","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib85","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","article-title":"Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and Follow-Up of treatment for osteoporosis","volume":"36","author":"Lorentzon","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.berh.2026.102206_bib86","article-title":"Expected change: a new concept for monitoring patients on oral bisphosphonates","volume":"23","author":"Schini","year":"2026","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"6","key":"10.1016\/j.berh.2026.102206_bib87","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"10.1016\/j.berh.2026.102206_bib89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12020-025-04275-y","article-title":"A practical use of bone turnover markers in management of patients with skeletal fragility","volume":"89","author":"Brunetti","year":"2025","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib90","doi-asserted-by":"crossref","first-page":"264","DOI":"10.11005\/jbm.24.789","article-title":"Clinical utility of bone turnover markers in chronic kidney disease","volume":"31","author":"Srisuwarn","year":"2024","journal-title":"J Bone Metab"},{"key":"10.1016\/j.berh.2026.102206_bib91","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bone.2014.05.016","article-title":"New developments in biological markers of bone metabolism in osteoporosis","volume":"66","author":"Garnero","year":"2014","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.berh.2026.102206_bib92","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40291-017-0272-1","article-title":"The utility of biomarkers in osteoporosis management","volume":"21","author":"Garnero","year":"2017","journal-title":"Mol Diagn Ther"},{"issue":"48","key":"10.1016\/j.berh.2026.102206_bib93","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","article-title":"The collagenolytic activity of cathepsin K is unique among mammalian proteinases","volume":"273","author":"Garnero","year":"1998","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.berh.2026.102206_bib94","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1359\/jbmr.2000.15.7.1337","article-title":"Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption","volume":"15","author":"Halleen","year":"2000","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"6937","key":"10.1016\/j.berh.2026.102206_bib95","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib96","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102206_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocd.2023.101452","article-title":"Clinical use of trabecular bone score: the 2023 ISCD official positions","volume":"27","author":"Goel","year":"2024","journal-title":"J Clin Densitom"},{"issue":"10","key":"10.1016\/j.berh.2026.102206_bib98","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.berh.2026.102206_bib99","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American association of clinical Endocrinologists\/American college of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of Postmenopausal Osteoporosis\u2014 2020 update executive Summary","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.berh.2026.102206_bib100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal Women: an Endocrine Society Guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.berh.2026.102206_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers","year":"2020","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.berh.2026.102206_bib102","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"19","key":"10.1016\/j.berh.2026.102206_bib103","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:29:46Z","timestamp":1792726186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":103,"alternative-id":["S1521694226000914"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102206","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of biomarkers in the management of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102206"}}